Asher Biotherapeutics’ proprietary cistargeting platform is at the core of its therapeutic innovation

Asher Biotherapeutics’ proprietary cistargeting platform is at the core of its therapeutic innovation. This technology allows for the precise targeting of specific immune cell types, leading to enhanced activation of desired immune responses while avoiding the activation of unwanted cells. This selective approach aims to improve the efficacy and safety of immunotherapies. By targeting specific receptors expressed only on desired immune cells,cis−targeting enables the precise modulation of immune responses, reducing the risk of systemic side effects.The cis−targeting platform can be applied to various therapeutic areas, including oncology and autoimmune diseases, providing a versatile tool for the development of targeted immunotherapies.Asher Biotherapeutics is committed to advancing its research and development efforts to bring innovative therapies to patients:The company’s pipeline includes both preclinical and clinical programs focused on addressing high unmet medical needs. Asher Biotherapeutics conducts rigorous studies to evaluate the safety and efficacy of its drug candidates.Asher Biotherapeutics collaborates with leading academic institutions, research organizations,and industry partners to enhance its R&D capabilities and accelerate the development of novel therapies.